Floxed Dll1 Mouse

Conditional Knock Out

Floxed Dll1 Conditional Knock Out Mouse Model
Inquire
CALL: 888.822.6642 + 45 70 23 04 05 (EUROPE)
This line is cryopreserved and requires cryorecovery.

B6;129 Background

  • Model #
  • Genotype
  • Nomenclature
  • 13074-F
    B6;129-Dll1tm1Mjo
  • 13074-M
    B6;129-Dll1tm1Mjo

  • May be used to generate constitutive or conditional knockouts of the Dll1 gene by crossing to the cre line of choice.
  • Dll1 is a Notch ligand
  • Useful for studies of Notch signaling, development, immune system development and function as well as autoimmune disease studies

Origin:

The Floxed Dll1 Mouse was developed by Katsuto Hozumi in the laboratory of Michael Owen at the Laboratory of Lymphocyte Molecular Biology, Cancer Research UK, and further developed and characterized by Rachael Brooker in the laboratory of Julian Lewis at the Vertebrate Development Laboratory, Cancer Research UK. The model was generated by targeting the Dll1 gene to generate a floxed allele in 129-derived ES cells. The targeting vector includes a loxP site inserted before exon 3 and a loxP-flanked resistance cassette after exon 4. Properly targeted ES cells were transfected with a Cre expression vector to excise the resistance cassette and injected into C57BL/6 blastocysts. Chimeric offspring were mated to C57BL/6 mice. Taconic received embryos from CRT in 2013.


Source:

Sponsor: Cancer Research Technology

Availability:

This model is available for immediate cryorecovery.

Species:

Mouse

Initial Publication:

Hozumi K, Negishi N, Suzuki D, Abe N, Sotomaru Y, Tamaoki N, Mailhos C, Ish-Horowicz D, Habu S, Owen MJ. (2004) Delta-like 1 is necessary for the generation of marginal zone B cells but not T cells in vivo. Nat Immunol. 5(6):638-44.


Access to this model requires execution of a Limited Breeding Agreement. Current Limited Breeding Agreement fees for this model are $2,500/year (€2000/year) for nonprofit users and $10,000/year (€8000) for for-profit users.

Purchase of line #13073 includes the right under the patents owned by Le Centre Européen de Recherche en Biologie et en Médecine ("CERBM") to perform inducible deletion (e.g. tamoxifen induction based deletion) using the CreER gene.